Bimekizumab in psoriatic arthritis: responses sustained across domains to three years

Design

Post hoc pooled analysis of two phase 3 RCTs and open-label extension

Population

1,112 patients with active psoriatic arthritis on bimekizumab 160 mg every 4 weeks

Primary outcome

Response across GRAPPA domains to week 148

Effect

ACR50 54.8%; PASI100 64.6%; dactylitis resolution 68.6%

This post hoc pooled analysis included 1,112 patients with active psoriatic arthritis from two phase 3 trials, one in biologic-naive patients and one after TNF inhibitor failure, and their open-label extension, all on bimekizumab 160 mg every four weeks. The analysis was industry-sponsored.

At three years, 54.8% had at least a 50% improvement in ACR criteria. Swollen joints had resolved in 59.2% and tender joints in 34.6%. Enthesitis resolved in 56.6% and dactylitis in 68.6%. Complete skin clearance was seen in 64.6% and nail clearance in 68.0%. Inflammatory bowel disease and uveitis events were rare.

Open-label extensions keep patients who are doing well, and imputation methods can flatter long-term response. There is no comparator after the first year.

The data are consistent with durable benefit across the different domains of psoriatic arthritis. Availability and cost in India should be checked; the choice among IL-17 and other agents still depends on the domains involved and on access.

• Consider IL-17A/F inhibition where skin, nail and joint disease all need control.
• Monitor for inflammatory bowel disease symptoms, although events were rare here.
• Assess each GRAPPA domain separately when judging response.
• Interpret long-term open-label figures as an upper estimate of real-world response.

Why it matters

Psoriatic arthritis affects skin, nails, entheses and joints, and long-term control across all of them is what patients need.

Don't overread it

This is a post hoc, open-label analysis without a comparator beyond the first year.

The statistics, in plain English

In open-label extensions, patients who stop for lack of benefit leave the analysis, so later response rates partly reflect who remained. Non-responder imputation counts drop-outs as failures and is the more conservative approach.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.